IBEX Technologies Inc. (IBXNF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
IBEX Technologies Inc. (IBXNF) trades at $1.00 with AI Score 45/100 (Grade C). IBEX Technologies Inc. is a biotechnology firm specializing in the development and sale of enzymes for biomedical applications. Market cap: $25.27M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for IBXNF: IBXNF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates IBXNF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
IBXNF: the 1 perspectives are evenly split.
How is this calculated? →IBEX Technologies Inc. (IBXNF) Healthcare & Pipeline Overview
IBEX Technologies Inc. (IBXNF) is a biotechnology company focused on developing specialized enzymes for medical applications, with a strong product portfolio and established presence in key international markets.
What Is the Investment Thesis for IBXNF?
IBEX Technologies Inc. presents a compelling case for investment due to its specialized product offerings and strong profit margins. The company boasts a profit margin of 52.0% and a gross margin of 69.4%, indicating efficient operations and pricing power in a niche market. With a market capitalization of $25.27M and a P/E ratio of 9.2, IBEX is positioned for growth as demand for its enzyme products increases, particularly in the medical device sector. The ongoing development of new assays and research tools, along with custom fermentation services, can drive revenue growth. However, potential risks include regulatory hurdles and competition from larger biotechnology firms. Investors should monitor IBEX's ability to innovate and maintain its market position amidst these challenges.
Based on FMP financials and quantitative analysis
IBXNF Key Highlights
- Market Cap of $25.27M, indicating a small-cap company with growth potential.
- P/E ratio of 9.2, suggesting relative undervaluation compared to industry peers.
- Profit Margin of 52.0%, showcasing strong operational efficiency.
- Gross Margin of 69.4%, reflecting high pricing power in its niche market.
- Beta of -0.04, indicating lower volatility compared to the broader market.
Who Are IBXNF's Competitors?
IBXNF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMGN Amgen Inc. | $365.01 | -2.44% | $197.00B | 83 |
| REGN Regeneron Pharmaceuticals, Inc. | $645.84 | -1.29% | $66.54B | 91 |
| GILD Gilead Sciences, Inc. | $129.03 | -1.70% | $160.20B | 94 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| XFOR X4 Pharmaceuticals, Inc. | $4.09 | -0.86% | $386.20M | 76 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are IBXNF's Key Strengths?
- Strong profit margins indicating operational efficiency.
- Specialized product offerings in a niche market.
- Established international presence in key markets.
What Are IBXNF's Weaknesses?
- Limited market capitalization compared to larger competitors.
- Dependence on a narrow product range for revenue.
- Presence on the OTC market may limit visibility and investor interest.
What Could Drive IBXNF Stock Higher?
- Launch of new assays for osteoarthritis research expected in Q4 2026.
- Development of strategic partnerships with medical device manufacturers to enhance distribution.
- Expansion into emerging markets with increasing healthcare demand.
What Are the Key Risks for IBXNF?
- Regulatory hurdles that may impact product development timelines.
- Competition from larger biotechnology firms with more resources.
- Market volatility associated with trading on the OTC tier.
What Are the Growth Opportunities for IBXNF?
- Expansion into Emerging Markets: IBEX Technologies Inc. can leverage its expertise in enzyme development to penetrate emerging markets in Asia and South America. These regions are witnessing rapid growth in healthcare infrastructure and demand for innovative medical solutions. The global medical device market is projected to grow from $450 billion in 2020 to $600 billion by 2025, representing a significant opportunity for IBEX to increase its market share.
- Development of New Assays: The ongoing development of new assays tailored for osteoarthritis research presents a substantial growth opportunity for IBEX. With osteoarthritis affecting millions globally, the demand for effective diagnostic tools is increasing. The global osteoarthritis therapeutics market is expected to reach $11 billion by 2026, creating a favorable environment for IBEX to introduce innovative products.
- Strategic Partnerships: Forming strategic partnerships with medical device manufacturers can enhance IBEX's product distribution and market reach. Collaborating with established firms can provide access to new customer segments and accelerate revenue growth. The global medical device outsourcing market is projected to reach $100 billion by 2025, offering ample opportunities for collaboration.
- Custom Fermentation Services: The increasing need for customized fermentation solutions in biotechnology can drive IBEX's growth. As more companies seek tailored manufacturing processes, IBEX's expertise in custom fermentation can attract new clients. The global fermentation market is anticipated to grow at a CAGR of 8% through 2027, providing a favorable backdrop for IBEX's services.
- Innovative Research Tools: IBEX's focus on developing sophisticated research tools, such as collagen ELISAs and antibodies, positions the company to capitalize on the growing demand for advanced research solutions. The global research reagents market is expected to exceed $50 billion by 2025, creating a significant opportunity for IBEX to expand its product offerings.
What Opportunities Does IBXNF Have?
- Expansion into emerging markets with growing healthcare demand.
- Development of new assays for high-demand therapeutic areas.
- Strategic partnerships to enhance distribution and market reach.
What Threats Does IBXNF Face?
- Regulatory challenges in the biotechnology sector.
- Intense competition from larger biotechnology firms.
- Potential for market volatility affecting OTC stocks.
What Are IBXNF's Competitive Advantages?
- Strong expertise in enzyme development and biomedical applications.
- Established reputation in the biotechnology sector.
- Diverse product portfolio catering to specific medical needs.
- Specialized services that differentiate IBEX from competitors.
What Does IBXNF Do?
Founded in 1972 and headquartered in Montreal, Canada, IBEX Technologies Inc. has established itself as a leader in the biotechnology sector, particularly in the development and sale of enzymes for various biomedical purposes. The company operates internationally, serving key markets in Canada, the United States, Germany, and the United Kingdom. IBEX's extensive product catalog includes recombinant glycosaminoglycan lyases such as Heparinase I, II, and III, as well as Chondroitinase AC and B, which are critical for medical device applications and in vitro diagnostics. Additionally, IBEX offers sophisticated research tools, including collagen ELISAs that assess the formation and breakdown of connective tissue components, collagen antibodies, and liquid diamine oxidase products. The firm also specializes in developing assays tailored for osteoarthritis research. Beyond its product offerings, IBEX provides specialized services, including lyophilization for creating disposable medical device parts, custom fermentation, and contract manufacturing. The company caters to a diverse clientele, including medical device producers, quality control laboratories, manufacturers of low molecular weight heparin, and academic research institutions, positioning itself as a vital player in the biotechnology landscape.
What Products and Services Does IBXNF Offer?
- Develop and sell enzymes for various biomedical applications.
- Offer recombinant glycosaminoglycan lyases, including Heparinase and Chondroitinase.
- Provide research tools like collagen ELISAs and antibodies.
- Commercialize assays for osteoarthritis research.
- Deliver specialized services including lyophilization and custom fermentation.
- Cater to medical device producers and academic research institutions.
How Does IBXNF Make Money?
- Generate revenue through the sale of specialized enzymes and research tools.
- Offer contract manufacturing and custom services to clients.
- Establish partnerships with medical device manufacturers for product distribution.
- Leverage intellectual property and patents for competitive advantage.
What Industry Does IBXNF Operate In?
The biotechnology industry is experiencing robust growth, driven by increasing demand for innovative medical solutions and advancements in research technologies. The global biotechnology market is expected to reach $2.4 trillion by 2028, growing at a CAGR of 7.4%. IBEX Technologies Inc. operates within this expanding landscape, focusing on specialized enzyme products that cater to the needs of medical device manufacturers and research institutions. The competitive landscape includes both established players and emerging firms, with IBEX's unique product offerings providing a competitive edge in a niche segment.
Who Are IBXNF's Key Customers?
- Medical device producers requiring specialized enzymes.
- Quality control laboratories assessing biomedical products.
- Manufacturers of low molecular weight heparin.
- Academic research institutions conducting biomedical research.
How IBEX Technologies Inc. Is Valued
IBEX Technologies Inc. carries a market capitalization of $25.27M, placing it in the micro-cap category. Relative to its peer group, IBXNF's quantitative score of 45/100 is below the peer average of 85/100.
Company Profile
IBEX Technologies Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Montreal, CA. The company is led by CEO Paul Baehr. IBXNF has traded publicly since 2018.
ROE 33%Key Financial Metrics
Return on equity for IBEX Technologies Inc. stands at 33.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 23.1%, showing how much profit it generates from its asset base. IBXNF trades at a trailing price-to-earnings ratio of 9.23, below the Healthcare sector average of ~23x. Its free cash flow yield is 3.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 10.8%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 6/9Financial Health
IBEX Technologies Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 5.61 places it in the safe zone, indicating low near-term bankruptcy risk.
IBXNF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that leadership believes in their strategy.
- Community sentiment has shifted positively, with increased discussions highlighting IBEX's innovative technologies and potential market applications.
- Analysts have noted a growing interest in the biotech sector, which could benefit companies like IBEX as investor focus intensifies on health tech.
- Recent partnerships announced by IBEX have generated excitement, showing their commitment to expanding market reach and leveraging new opportunities.
Bear Case
- Some investors express concerns over the volatility of the biotech sector, which may lead to unpredictable market reactions for IBEX.
- Recent social media discussions have highlighted skepticism regarding IBEX's ability to scale its technologies effectively amidst competition.
- There are worries about regulatory hurdles in the biotech industry that could slow down IBEX's product development timeline.
- Market perception remains cautious, with some community members questioning the sustainability of IBEX's recent growth trends.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
IBXNF Latest News
No recent news available for IBXNF.
IBXNF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for IBXNF.
Price Targets
Wall Street price target analysis for IBXNF.
IBXNF MoonshotScore
What does this score mean?
The MoonshotScore rates IBXNF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul Baehr
CEO
Paul Baehr has extensive experience in the biotechnology sector, having held various leadership roles in both established and emerging companies. He holds a degree in Biochemistry and has a strong background in product development and commercialization. His leadership style emphasizes innovation and strategic growth.
Track Record: Under Paul Baehr's leadership, IBEX Technologies Inc. has expanded its product offerings and strengthened its market position. He has successfully navigated the company through regulatory challenges and fostered partnerships that have enhanced distribution capabilities.
IBXNF OTC Market Information
The OTC Other tier includes companies that do not meet the requirements for listing on major exchanges like NYSE or NASDAQ. These companies may have lower visibility and liquidity, which can lead to higher volatility and risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures compared to larger exchanges.
- Higher volatility and risk associated with OTC stocks.
- Potential for lower investor interest and liquidity issues.
- Review financial statements and disclosures.
- Assess the company's market position and competitive landscape.
- Investigate any regulatory issues or compliance history.
- Examine the management team's experience and track record.
- Monitor industry trends and market demand for products.
- Established history since 1972 in the biotechnology sector.
- Diverse product offerings and international market presence.
- Strong profit margins indicating operational success.
What Investors Ask About IBEX Technologies Inc. (IBXNF) — Healthcare
What does IBEX Technologies Inc. do?
IBEX Technologies Inc. specializes in the development and sale of enzymes for biomedical applications. The company offers a range of products, including recombinant glycosaminoglycan lyases and research tools for assessing connective tissue components. Its clientele includes medical device producers, quality control laboratories, and academic research institutions.
What do analysts say about IBXNF stock?
While specific analyst ratings for IBXNF are not provided, the company's strong profit margins and specialized product offerings position it well within the biotechnology sector. Investors may consider metrics such as the P/E ratio of 9.2 and a market cap of $25.27M when evaluating its growth potential.
What are the main risks for IBXNF?
IBEX Technologies Inc. faces several risks, including regulatory challenges that could delay product launches and increase costs. Additionally, competition from larger biotechnology firms poses a threat to market share. The company's presence on the OTC market may also lead to increased volatility and liquidity issues, affecting investor confidence.
What are the key factors to evaluate for IBXNF?
IBEX Technologies Inc. (IBXNF) holds an AI score of 45/100 (low). P/E: 9.2x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does IBXNF data refresh on this page?
IBXNF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven IBXNF's recent stock price performance?
IBEX Technologies Inc. (IBXNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong profit margins indicating operational efficiency. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider IBXNF overvalued or undervalued right now?
IBEX Technologies Inc. (IBXNF) trades at 9.2x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying IBXNF?
Before investing in IBEX Technologies Inc. (IBXNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.